Indication

Pathological Response

1 clinical trial

1 product

Clinical trial

A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma

Status: Recruiting, Estimated PCD: 2024-12-31

Product